News | June 22, 2022
AstraZeneca and Merck announces results from phase 3 PROpel trial of Lynparza
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
Alliances with CVS Health and Javara further embed clinical research into the community healthcare setting, expanding access to patient populations across the U.S to increase diversity in clinical trials
First and only FDA-approved device of its kind demonstrates consistently high rates of target limb salvage and freedom from clinically-driven target lesion revascularization
Amarex Clinical Research guides its client to phase II of FDA trials
TAK-003 is currently undergoing regulatory review for potential licensure in both the European Union
Marinus has broadened inclusion criteria in the RAISE trial to allow for enrollment of patients previously treated with IV anesthesia.
Scemblix (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif (bosutinib) at 96 weeks
Trial will assess safety and antibody responses of NVX-CoV2515 to the Omicron variant of COVID-19
Low-dose atropine has emerged as an effective approach to slow the progression of myopia in children
Results from the DELIVER and DAPA-HF Phase III trials demonstrate Dapagliflozin’ efficacy in heart failure regardless of ejection fraction
Subscribe To Our Newsletter & Stay Updated
